ArticleBMC women's health2026
Development and validation of a malignant risk prediction model for breast cystic-solid lesions based on clinical and ultrasound features.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAccurate differentiation of benign and malignant breast cystic-solid lesions (BCSLs) is crucial due to the significant differences in their treatment strategies. This study aimed to develop and validate a malignant risk prediction model for BCSLs based on clinical and ultrasound (US) features.
methodsA total of 312 patients with BCSLs were enrolled and divided into a training cohort (218 cases) and a validation cohort (94 cases). The least absolute shrinkage and selection operator (LASSO) was used to screen the most critical clinical and US features, and a prediction model was constructed using logistic regression. Calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA) were applied to evaluate the model’s performance and clinical value.
resultsFive key features were identified through LASSO regression: age, maximum diameter, edge, calcification in the solid component, and vascularity in the solid component. A prediction model was subsequently established and visualized as a nomogram. Calibration curves demonstrated good consistency of the model. The area under the curve (AUC) values of the training and validation cohorts were 0.821 (95% CI = 0.764–0.879) and 0.837 (95% CI = 0.754–0.919), respectively. DCA indicated that the model had practical value in clinical application.
conclusionThe prediction model based on clinical and US features can accurately predict the malignant risk of BCSLs and optimize clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.